Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen has recently made a significant move in the field of rare diseases with its $165 million partnership with Stoke Therapeutics to develop zorevunersen, a potential treatment for Dravet syndrome, a severe genetic epilepsy. This collaboration is set against the backdrop of Biogen's ongoing challenges with declining sales from its...

Biogen Partners with Stoke Therapeutics in $165 Million Deal to Develop Dravet Syndrome Treatment zorevunersen